Agios Shares Plunge After Novo Nordisk Reports Positive Sickle Cell Results
Agios Pharmaceuticals stock dropped 25% after Novo Nordisk announced positive trial results for its experimental sickle cell therapy etavopivat. Novo reported a 27% reduction in vaso-occlusive crisis events and roughly a four-month delay to the first such event versus standard of care. Agios is pursuing an accelerated approval path with the FDA for…